Efficacy and safety of biodegradable polymer biolimus A9-eluting stent versus durable polymer everolimus-eluting stent in diabetic patients: a prospective non-randomized single-centre long-term comparison

Sprimont, Pierre; Piérard, Sophie; Vanoverschelde, Jean–Louis; Debbas, Nadia

doi:10.1080/ac.69.5.3044879

Cited by 4 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…23 However, a nonrandomized study comparing the 20-month efficacy and safety of the biodegradable polymer N-BES and the reference durable polymer EES in diabetic patients showed no significant differences. 5 Compared to our results, the mortality rate in the N-BES group for diabetic patients was lower. This is probably related to differences in the indications for PCI (more patients with ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in our study: 48.5% vs 23%), comorbidity or patient selection.…”

Section: Outcomecontrasting

confidence: 87%

“…However, a nonrandomized study comparing the 20‐month efficacy and safety of the biodegradable polymer N‐BES and the reference durable polymer EES in diabetic patients showed no significant differences . Compared to our results, the mortality rate in the N‐BES group for diabetic patients was lower.…”

Section: Discussionmentioning

confidence: 82%

“…Compared to our results, the mortality rate in the N‐BES group for diabetic patients was lower. This is probably related to differences in the indications for PCI (more patients with ST‐segment elevation myocardial infarction and non‐ST‐segment elevation myocardial infarction in our study: 48.5% vs 23%), comorbidity or patient selection …”

Section: Discussionmentioning

confidence: 99%

“…This is probably related to differences in the indications for PCI (more patients with ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in our study: 48.5% vs 23%), comorbidity or patient selection. 5 The geometry of newer biodegradable polymer DES has been improved with a significant reduction of strut thickness. As compared to N-BES, which was the first DES with a biodegradable polymer, the newer O-SES has significantly thinner stent struts (60-80 μm compared to the 120 μm for the N-BES).…”

Section: Outcomementioning

confidence: 99%

“…In order to improve biocompatibility and long‐term safety, the new biodegradable polymer DESs have been designed to reduce chronic local inflammation by degradation of the polymer coating after complete elution of the antiproliferative drug. Compared with durable polymer EES, the biodegradable polymer Nobori biolimus‐eluting stent (N‐BES) showed similar long‐term efficacy and safety in this specific population of diabetic patients . In a substudy of the “ultrathin strut biodegradable polymer sirolimus‐eluting stent versus durable‐polymer everolimus‐eluting stent for percutaneous coronary revascularization (BIOSCIENCE) trial”, the clinical outcomes among diabetic patients treated with biodegradable polymer Orsiro sirolimus‐eluting stent (O‐SES) or durable polymer EES were comparable at 1 year .…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Impact of diabetes on clinical outcomes after revascularization with sirolimus‐eluting and biolimus‐eluting stents with biodegradable polymer from the SORT OUT VII trial

Ellert-Gregersen

Christiansen

Mæng

et al. 2018

Cathet Cardio Intervent

View full text Add to dashboard Cite

Objectives In this substudy of the SORT OUT VII trial, the clinical outcomes among patient with diabetes mellitus treated with Orsiro sirolimus‐eluting stent (O‐SES; Biotronik, Bülach, Switzerland) or Nobori biolimus‐eluting stent (N‐BES; Terumo, Tokyo, Japan) were compared. Background Diabetes is associated with increased risk of target lesion failure (TLF) after percutaneous coronary intervention. Methods In total, 2525 patients were randomized to stent implantation with O‐SES (n = 1261, diabetes: n = 236) or N‐BES (n = 1264, diabetes: n = 235). The primary endpoint, TLF, was a composite of cardiac death, target‐lesion myocardial infarction (MI), or target lesion revascularization (TLR) within 2 years. Results At 2 year, TLF did not differ between O‐SES vs N‐BES in diabetic (9.3% vs 9.4%; RR 0.98, 95% CI 0.54–1.78) patients. The individual components of the primary endpoint did not differ among stent type. In diabetics, cardiac death occurred in 3% of O‐SES‐treated and in 3.8% of N‐BES‐treated patients (RR 0.77, 95% CI 0.29–2.08), MI occurred in 3.0% of O‐SES‐treated and in 3.8% of N‐BES‐treated patients (RR 0.76, 95% CI 0.28–2.06) and TLR occurred in 5,5% of O‐SES‐treated and in 6.0% of N‐BES‐treated patients (RR 0.91, 95% CI 0.43–1.95). Conclusion TLF did not differ between O‐SES‐ and N‐BES‐treated diabetic patients.

show abstract

Section: Outcomecontrasting

confidence: 87%

Section: Discussionmentioning

confidence: 82%

Section: Discussionmentioning

confidence: 99%

Section: Outcomementioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Impact of diabetes on clinical outcomes after revascularization with sirolimus‐eluting and biolimus‐eluting stents with biodegradable polymer from the SORT OUT VII trial

Ellert-Gregersen

Christiansen

Mæng

et al. 2018

Cathet Cardio Intervent

View full text Add to dashboard Cite

show abstract

Combination of a biodegradable three-dimensional (3D) – printed cage for mechanical support and nanofibrous membranes for sustainable release of antimicrobial agents for treating the femoral metaphyseal comminuted fracture

Chou

Lee

Chang

et al. 2017

Journal of the Mechanical Behavior of Biomedical Materials

View full text Add to dashboard Cite

Five-year outcomes of patients with diabetes mellitus treated with a sirolimus-eluting or a biolimus-eluting stents with biodegradable polymer. From the SORT OUT VII trial

Trøan,

Christiansen,

Hansen

et al. 2024

Diabetes and Vascular Disease Research

View full text Add to dashboard Cite

Background Diabetes mellitus is associated with higher risk of target lesion failure (TLF) after percutaneous coronary intervention. We studied the 5-year outcome in patients with diabetes mellitus treated with biodegradable polymer stents. Methods The SORT OUT VII was a randomised trial comparing the ultrathin sirolimus-eluting Orsiro stent (O-SES) and the biolimus-eluting Nobori stent (N-BES) in an all-comer setting. Patients ( n = 2525) were randomised to receive O-SES ( n = 1261, diabetes: n = 236) or N-BES ( n = 1264, diabetes: n = 235). Endpoints were TLF (a composite of cardiac death, target-lesion myocardial infarction (MI), target lesion revascularization (TLR)), definite stent thrombosis and a patient related outcome (all-cause mortality, MI and revascularization) within 5 years. Results Patients with diabetes mellitus had higher TLF (20.6% vs 11.0%, (Rate ratio (RR) 1.85 95% confidence interval (CI): (1.42-2.40) and patient related outcome (42.0% vs 31.0%, RR 1.43 95% CI: (1.19-1.71)) compared to patients without diabetes. Among patients with diabetes mellitus, TLF after 5 years did not differ between O-SES and N-BES (21.2% vs 20.0%), RR 1.05 95% CI: (0.70-1.58), p = 0.81). Cardiac death, MI, TLR, and definite stent thrombosis did not differ between the groups. Conclusion In patients with diabetes mellitus, 5-year outcomes were similar among patients treated with biodegradable polymer O-SES or N-BES. Clinical trial registration URL: https://www.clinicaltrials.gov . Unique identifier: NCT01879358.

show abstract

Efficacy and safety of biodegradable polymer biolimus A9-eluting stent versus durable polymer everolimus-eluting stent in diabetic patients: a prospective non-randomized single-centre long-term comparison

Cited by 4 publications

References 0 publications

Impact of diabetes on clinical outcomes after revascularization with sirolimus‐eluting and biolimus‐eluting stents with biodegradable polymer from the SORT OUT VII trial

Impact of diabetes on clinical outcomes after revascularization with sirolimus‐eluting and biolimus‐eluting stents with biodegradable polymer from the SORT OUT VII trial

Combination of a biodegradable three-dimensional (3D) – printed cage for mechanical support and nanofibrous membranes for sustainable release of antimicrobial agents for treating the femoral metaphyseal comminuted fracture

Five-year outcomes of patients with diabetes mellitus treated with a sirolimus-eluting or a biolimus-eluting stents with biodegradable polymer. From the SORT OUT VII trial

Contact Info

Product

Resources

About